Markers to sensibility and relapse on IMR-32 neuroblastoma cell line cultured in monolayer (2D) and neurosphere (3D) models cisplatin-treated.
Autor: | Gonçalves BÔP; Cellular Biology, Research and Development Department, Ezequiel Dias Foundation, Belo Horizonte, Minas Gerais 30510-010, Brazil; Department of Physiology and Byophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil., de Andrade WP; Hematology and Oncology Nucleus, Oncoclinics, Belo Horizonte, MG, Brazil., Fialho SL; Pharmaceutical Research and Development, Ezequiel Dias Foundation, Belo Horizonte, Minas Gerais 30510-010, Brazil., Silva LM; Cellular Biology, Research and Development Department, Ezequiel Dias Foundation, Belo Horizonte, Minas Gerais 30510-010, Brazil. Electronic address: lucianam.maria.silva@gmail.com. |
---|---|
Jazyk: | angličtina |
Zdroj: | Acta histochemica [Acta Histochem] 2022 Feb; Vol. 124 (2), pp. 151849. Date of Electronic Publication: 2022 Jan 13. |
DOI: | 10.1016/j.acthis.2022.151849 |
Abstrakt: | The complexity of different components of tumor stroma poses huge challenges for therapies targeting the neuroblastoma (NB) microenvironment. The present study aimed to evaluate platinum-based response in IMR-32 neuroblastoma cell line cultured in monolayer (2D) and neurosphere (3D) models. For this, we evaluated mRNA expression of heat shock proteins HSPA1A, HSPB1, TRAP1, HSPA1AL, HSPD1, and DNA damage repair gene ERCC1. After treatment, residual cells were grafted on CAM (chicken chorioallantoic membrane) to evaluate the growth capability and histological paraffin sections were made to assess Ki-67 and HER-2 proteins by immunofluorescence. Our results showed that cisplatin induces mRNA downregulation of Heat Shock Proteins and ERCC1 in IMR-32 cells cultured in 2D or 3D models. In addition, the cisplatin-treatment approach increased HER-2 expression in residual IMR-32 cells grafted on the CAM. Therefore, these insights provide many advances in neuroendocrine tumor biology and knowledge about cisplatin-response in neuroblastoma. (Copyright © 2022 Elsevier GmbH. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |